A multi-analyte blood test combining cell-free DNA (cfDNA) methylation patterns and protein tumor markers.
available now for CLINICAL use
HelioLiver LDT is a new, non-invasive blood test that detects DNA markers associated with a higher risk of hepatocellular carcinoma (HCC). HelioLiver LDT can be done using a simple blood draw during a regular physician visit, eliminating the need for a separate appointment at an imaging lab.
Powered by advanced AI and machine learning, HelioLiver LDT is the first blood test to use methylation to detect early-stage liver cancer, offering new hope to patients and healthcare providers. Early detection opens up more curative treatment options, improving outcomes for all.
Today, less than 20% of at-risk patients receive recommended testing for HCC
Guidelines recommend routine HCC surveillance for cirrhosis, typically with an ultrasound every six months. However, fewer than 20% of patients receive the recommended testing.
Why?
| HELIOLIVER | ULTRASOUND | |
|---|---|---|
| Sensitivity for Lesions <2cm | 29% | 0% |
| Sensitivity for Stage 1 HCC | 44% | 11% |
| Turnaround Time | 10-14 days | ~20 days |
| Surveillance Method | Blood Draw (~5 min) | Imaging (30-60 min) |
| Scheduling | Same Day at Doctor’s Office | Separate Appointment at Imaging Center |
| Analysis Method | Analysis of Liver Serum Levels + Methylation Signals from DNA | Visual Scan |
Presenter: Shivani Mahajan, Head of Computational Science at Helio Genomics
Length: 5:19 minutes
Ordering the HelioLiver test is simple and straightforward
Routine surveillance is critical for patients to catch cancer early before it spreads. We partner with physicians to help ensure patients maintain the recommended schedule for liver cancer testing.
Testing intervals for HCC surveillance consider the tumor doubling time and the cost of the surveillance test. Guidelines recommend patients at high risk for HCC, such as cirrhosis, undergo surveillance every 6 months
Order Now